Application 201503
- Type
- ANDA
- Sponsor
- APOTEX CORP
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CABERGOLINE | CABERGOLINE | TABLET;ORAL | 0.5MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A201503-001 | CABERGOLINE | CABERGOLINE | 0.5MG | TABLET / ORAL | 2013-03-08 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-09-29 23:25 UTC | 2022-09 | A201503-001 | CABERGOLINE | 0.5MG | TABLET / ORAL | 2013-03-08 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A201503-001 | CABERGOLINE | 0.5MG | TABLET / ORAL | 2013-03-08 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A201503-001 | CABERGOLINE | 0.5MG | TABLET / ORAL | 2013-03-08 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cabergoline | CABERGOLINE | Mylan Pharmaceuticals Inc. | e497366b-a124-4d7f-bd45-a883c392d4bb | 2026-06-30 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| CABERGOLINE | CABERGOLINE | Cranbury Pharmaceuticals, LLC | 8562f94f-a59a-4893-aefc-ea6547b01e92 | 2026-06-22 | Warnings, Adverse reactions | CABERGOLINE CABERGOLINE |
| Cabergoline | CABERGOLINE | A-S Medication Solutions | c9f0b576-d5e5-4e3e-bb5c-3574d75d9907 | 2026-03-19 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| Cabergoline | CABERGOLINE | SOLA Pharmaceuticals, LLC | 275a6a25-c3c9-4258-a610-0b00752517f7 | 2025-12-08 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| Cabergoline | CABERGOLINE | A-S Medication Solutions | 9405c116-4a77-4e14-9ab8-25e899595cdf | 2025-08-27 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| Cabergoline | CABERGOLINE | Ingenus Pharmaceuticals, LLC | 57cbd81e-fdb9-4060-80ee-6e8581c463a4 | 2025-07-04 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| Cabergoline | CABERGOLINE | Teva Pharmaceuticals USA, Inc. | 74b61e8a-7ae9-4996-85ec-df23c56de16f | 2025-06-16 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| CABERGOLINE | CABERGOLINE | Somerset Therapeutics, LLC | e0fb5556-de2c-4822-9960-0700e2907890 | 2024-11-14 | Warnings, Adverse reactions | CABERGOLINE CABERGOLINE |
| Cabergoline | CABERGOLINE | Amneal Pharmaceuticals NY LLC | a246b015-e19c-4b4f-9089-aea1108687ba | 2024-10-03 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| Cabergoline | CABERGOLINE | A-S Medication Solutions | 7699d938-3f62-4e13-9b33-3e581310b9f3 | 2023-08-28 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| Cabergoline | CABERGOLINE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | bc44d11b-b3f0-4e3d-9da3-4f8852d11734 | 2023-07-27 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
| Cabergoline | CABERGOLINE | A-S Medication Solutions | 89ec147b-a6fe-49bb-9af5-52fc2ce5db7f | 2023-04-12 | Warnings, Adverse reactions | Cabergoline CABERGOLINE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.